Loading
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Latest filing published 26 Jan 2021 for Eidos Therapeutics, Inc..
Insider track record
Disclosed buys
3
Disclosed sells
0
Signal history
Closed purchases
Market purchases
3
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
BridgeBio Pharma, Inc.: trading record in brief
All filings by BridgeBio Pharma, Inc. on record concern Eidos Therapeutics, Inc. Over a trading history stretching from 24 May 2019 to 26 January 2021, the count stands at 3 filings.
Every open-market trade on record is a purchase: 3 purchases worth €49.0M, and no sale. No amount is published for 1 filing, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2021, the count stands at 1 purchase and no sales.
The record was last updated on 26 January 2021 with an open-market purchase in Eidos Therapeutics, Inc. Typically, a trade is published a median of 5 days after it takes place. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to BridgeBio Pharma, Inc.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations1 total
14,428,836 sharesCommon StockSEC:0000899243-21-003286:0
Canonical exit: 26 Apr 2021 (T+90)
882,353 shares@ US$29.9047.7% of flowCommon StockSEC:0000899243-19-019337:0
Canonical exit: 1 Oct 2019 (T+90)
1,103,848 shares@ US$25.9352.3% of flowCommon StockSEC:0000899243-19-015088:0
Canonical exit: 22 Aug 2019 (T+90)
3 of 1 declaration
